Table 1.
Demographics of the 92 Participants Who Contributed Cross-Sectional and Longitudinal (n = 57) Data, a Subset of the Total 216 Participants Randomized Within the Sabes Clinical Study
| Variable | Enrolled Within 30 Days of EDDI (n = 32) | Enrolled 31–100 Days From EDDI (n = 65) | P Value |
|---|---|---|---|
| Male sex at birth | 32 (100) | 65 (100) | 1.00 |
| Gender identity | 29 (91) | 57 (88) | .25 |
| Male | |||
| Transgender female | 2 (6) | 8 (12) | |
| Other/not reported | 1 (3) | 0 (0) | |
| Age, y, mean (IQR) | 26.4 (22.8–29.7) | 27.0 (21.3–30.2) | .63 |
| PEth results at ENRa, ng/mL | .43 | ||
| <8 (negative) | 14 (44) | 28 (43) | |
| 8–111 | 14 (44) | 24 (37) | |
| ≥112 | 0 (0) | 3 (5) | |
| Not available | 4 (12) | … | |
| Current smoking | 16 (50) | 25 (38) | .28 |
| Cocaine use (any form) | 1 (3) | 3 (5) | .73 |
| Marijuana | 3 (9) | 6 (9) | .98 |
| CD4 at ENRa, median (IQR) | 406 (276–543) | 428 (284–571) | .96 |
| HIV VL at ENRa, log10 median (IQR) | 6.7 (6.2–7.0) | 5.4 (4.7–6.0) | <.0001 |
Data are presented as No. (%) unless otherwise indicated. Few, if any, participants (1 or none each) reported any use of inhalants, amphetamines, opioids, or hallucinogens and are therefore omitted from these tables.
Abbreviations: EDDI, estimated date of detectable infection; ENR, enrollment; HIV, human immunodeficiency virus; IQR, interquartile range; PEth, phosphatidylethanol, a long-lived alcohol metabolite; VL, viral load.
ENR was generally within 6 days of diagnosis of acute or primary HIV.